14. Chronic inflammatory demyelinating polyneuropathy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 175 / Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24
Chronic inflammatory demyelinating polyneuropathy and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
ID | Diseases (Sorted by drug repositionability) |
---|---|
14 | Chronic inflammatory demyelinating polyneuropathy |
13 | Multiple sclerosis/Neuromyelitis optica |
11 | Myasthenia gravis |
6 | Parkinson disease |
12 | Congenital myasthenic syndrome |
50 | Dermatomyositis |
3 | Spinal muscular atrophy |
222 | Primary nephrotic syndrome |
28 | Systemic amyloidosis |
49 | Systemic lupus erythematosus |
4 | Primary lateral sclerosis |
83 | Addison disease |
61 | Autoimmune hemolytic anemia |
331 | Idiopathic multicentric castleman disease |
66 | IgA nephropathy |
60 | Aplastic anemia |
65 | Primary immunodeficiency |
85 | Idiopathic interstitial pneumonia |
96 | Crohn disease |
2 | Amyotrophic lateral sclerosis |
46 | Malignant rheumatoid arthritis |
43 | Microscopic polyangiitis |
300 | IgG4-related disease |
44 | Wegener granulomatosis |
35 | Pemphigus |
52 | Mixed connective tissue disease |
220 | Rapidly progressive glomerulonephritis |
30 | Distal myopathy |